PDCD1 and melanoma: Immune checkpoint inhibitors (ICIs) that target cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) have revolutionized the treatment of malignant melanoma (1).